Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

nordic group bv - ni podatka - tableta - ni podatka - mizoprostol

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

n. v. organon, oss - ni podatka - prašek in vehikel za raztopino za injiciranje - ni podatka - horionski gonadotropin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

n. v. organon, oss - ni podatka - prašek in vehikel za raztopino za injiciranje - ni podatka - horionski gonadotropin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pliva ljubljana d.o.o., ljubljana - ni podatka - filmsko obložena tableta - ni podatka - risperidon

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pliva ljubljana d.o.o., ljubljana - ni podatka - filmsko obložena tableta - ni podatka - risperidon

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pliva ljubljana d.o.o., ljubljana - ni podatka - filmsko obložena tableta - ni podatka - risperidon

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

accord healthcare - ni podatka - koncentrat za raztopino za infundiranje - ni podatka - paklitaksel

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

nordic group bv - ni podatka - tableta - ni podatka - mizoprostol

Evropska unija - slovenščina - EMA (European Medicines Agency)

mylan pharmaceuticals limited - darunavir - okužbe z virusom hiv - antivirusi za sistemsko uporabo - darunavir, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv-1) infection (see section 4. darunavir mylan 75 mg, 150 mg, 300 mg and 600 mg tablets may be used to provide suitable dose regimens (see section 4. 2):za zdravljenje okužbe z virusom hiv-1 okužba v protiretrovirusno zdravljenje (art)-izkušeni odraslih bolnikih, vključno s tistimi, ki so bili zelo pre-obravnava. za zdravljenje okužbe z virusom hiv-1 okužba pri pediatričnih bolnikih od starosti 3 let in najmanj 15 kg telesne teže. pri odločanju za uvedbo zdravljenja z darunavir co-daje z nizkim odmerkom ritonavir, previdni, upoštevati je treba zdravljenje zgodovino posameznih bolnikov in vzorcev mutacije, povezane z različnimi agenti. genotypic or phenotypic testing (when available) and treatment history should guide the use of darunavir (see sections 4. 2, 4. 4 in 5. darunavir co-daje z nizkim odmerkom ritonavir je navedeno v kombinaciji z drugimi protiretrovirusnimi zdravili za zdravljenje bolnikov z virusom humane imunske pomanjkljivosti (hiv-1) okužbe.  darunavir co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg) (see section 4.  darunavir mylan 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are: antiretroviral therapy (art)-naïve (see section 4.  art-experienced with no darunavir resistance associated mutations (drv-rams) and who have plasma hiv-1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 10⁶/l. pri odločanju za uvedbo zdravljenja z darunavir v takih art-izkušeni bolniki, genotipa testiranje mora vodnik za uporabo darunavir (glej točki 4. 2, 4. 3, 4. 4 in 5.

Evropska unija - slovenščina - EMA (European Medicines Agency)

les laboratoires servier - trifluridine, tipiracil hidroklorid - kolorektalne neoplazme - antineoplastična sredstva - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.